Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18776477 | 0.96 | CYP3A4 (0.67) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3821727 | 0.94 | CYP3A4 (0.58) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3823374 | 0.92 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3819577 | 0.92 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3820526 | 0.92 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL17470436 | 0.88 | CYP3A4 (0.52) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL18776473 | 0.88 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL27568460 | 0.88 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL28762852 | 0.88 | CYP3A4 (0.56) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL6899778 | 0.87 | CYP3A4 (0.50) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014843-A1 | Vapor pressure depressant and use thereof | DAIHACHI CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-01-19 | — | — | US | claimed |
| EP-1561793-A1 | VAPOR PRESSURE DEPRESSANT AND USE THEREOF | Daihachi Chemical Industry Co., Ltd. (JP) | 2005-08-10 | — | — | EP | claimed |
| US-20240058768-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2024-02-22 | — | — | US | disclosed |
| EP-4277731-A1 | MEMBRANE FOR WATER FILTRATION | Aquaporin A/S (DK) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152748-A1 | MEMBRANE FOR WATER FILTRATION | AQUAPORIN A/S (DK) | 2022-07-21 | — | — | WO | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| EP-2445502-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-06-21 | — | — | EP | disclosed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-9580417-B2 | Prodrugs of heteraromatic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-02-28 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-6878278-B2 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6723241-B2 | COMPRISING A POLYAMIDE LAYER ON A POROUS SUPPORT WHERE THE POLYAMIDE LAYER IS COMPLEXED OR HYDROGEN BONDED TO A PHOSPHORUS-CONTAINING COMPOUND; IMPROVED FLUX AND/OR REJECTION RATE; FILTERS; NANOFILTRATION AND REVERSE OSMOSIS | DOW GLOBAL TECHNOLOGIES INC. | 2004-04-20 | — | — | US | disclosed |
| US-20030116498-A1 | Composite membrane and method for making the same | THE DOW CHEMICAL COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-6562266-B2 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1276551-A2 | COMPOSITE MEMBRANE AND METHOD FOR MAKING THE SAME | DOW GLOBAL TECHNOLOGIES INC. (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020113008-A1 | Composite membrane and method for making the same | THE DOW CHEMICAL COMPANY | 2002-08-22 | — | — | US | disclosed |
| US-6337018-B1 | COATING POROUS SUPPORT WITH SOLUTION OF POLYFUNCTIONAL AMINE AND SOLUTION OF POLYFUNCTIONAL ACYL HALIDE WHICH REACT TO FORM POLYAMIDE LAYER, INCLUDING STEP OF CONTACTING PHOSPHOROUS COMPOUND WITH ACYL HALIDE BEFORE REACTING WITH AMINE | THE DOW CHEMICAL COMPANY | 2002-01-08 | — | — | US | disclosed |
| US-20010050252-A1 | Composite membrane and method for making the same | DOW GLOBAL TECHNOLOGIES LLC | 2001-12-13 | — | — | US | disclosed |
| WO-2001078882-A2 | COMPOSITE MEMBRANE AND METHOD FOR MAKING THE SAME | DOW GLOBAL TECHNOLOGIES INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | CYP3A4 16/4885TSHR 4488/4885LPAR3 4841/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | CYP3A4 16/4885TSHR 4488/4885LPAR3 4841/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | CYP3A4 733/4885TSHR 3738/4885LPAR3 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.